sameAs
Colony stimulating factor 1 receptorPlatelet derived growth factor receptor alphaPlatelet derived growth factor receptor betaFms related receptor tyrosine kinase 1Fms related receptor tyrosine kinase 4Kinase insert domain receptorFms related receptor tyrosine kinase 3KIT proto-oncogene, receptor tyrosine kinase
P129
Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerPhase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid TumorsA Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOXAZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver CancerCediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaAZD2171 and Temsirolimus in Patients With Advanced Gynecological MalignanciesA Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in JapanPhase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic TumorsPhase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourA Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid TumorsPhase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AMLStudy to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate CancerPhase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced CancerPhase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver MetastasesWIRE - Novel Treatments in Renal Cell CancerAZD2171 and Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid MalignanciesA Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive GlioblastomaBest Approach in Recurrent-Ovarian-Cancer-with Cediranib-OlaparibA Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsOlaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial CancerCediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerAn uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
P4844
Q21100975-2AEF163F-F478-4D51-94DC-6264ED7043A5Q21102511-A25F55A3-6D98-4DAD-9364-61BF9A83014EQ21108624-EB291E87-01CD-44EB-A265-5F0A0AA8F75FQ21115605-B7AB391F-BF02-4D6C-ACEA-A8B4A022D453Q21118353-108B784D-CABA-4C28-81A9-1200AF7243B0Q21172390-22A920A9-FC04-4FE9-AA74-5A128931A9A5Q5009781-91203287-7A87-42AF-82B4-83FC089F45ABQ909409-B3C446C1-4E26-4D4C-8E38-92F39386D5EB
P129
Q61864697-9D4891E9-B3F4-4020-A463-68FD367CDBA7Q61865057-199D31D0-BA97-4B96-BE53-A7D506F64B43Q61865543-B8B6BC60-64D6-403B-9C97-2109EFC7C067Q61917723-C3779590-74C7-40F0-962F-E795327EB2C9Q61920684-D80AE649-9147-43AE-9B65-ECB1B7CC54DAQ61921310-48E8E351-1E27-45B0-9236-07202F2508B7Q61921697-15D97FA1-22E6-46AB-A820-C5AD66D5F381Q61939348-C38965FB-00A2-4251-A53C-4DA9E38D2598Q61980164-54EE74B7-C869-4506-AEF6-B8A92364E12FQ61980171-BAA8490A-C7C5-4572-8B6C-282AEBC6C045Q61980188-3BEF43A5-8BDF-46E3-A654-FB4053AF4D7BQ61980236-7FB5E08A-374E-41FC-9DEB-B34C38B28A9AQ61980250-22CDA39E-83B6-4A84-84B4-294F033B6D46Q61980269-F2AE8490-92E2-4E2C-8854-D21E408FFD71Q61980281-71F10DED-148C-4D75-BF08-98D7401E05D3Q61980323-0AF194DF-0AF7-4FF4-841D-3EC289BC21B6Q62034844-C6A60EE5-97FC-44D1-A21E-A5628D295C00Q62105635-5E1F9F18-C8DA-4960-9CA0-A9A74FA06D28Q63334289-E66850D1-A28C-4E6D-991B-203972233E7BQ63335616-67E7ADAC-A007-4292-B154-C1C5597A6EBCQ63339251-61FA7F75-0C70-477D-8103-A9AB7FEE328FQ63570888-2A430EE1-D090-4F0B-A0AD-B2AE63B95EA4Q63571340-E33BA5FB-C4F3-41FF-9743-3C98F655799EQ63571541-E03F9F7F-E9DD-495B-AEA4-904572692BB5Q63578928-3E3C3C55-A671-4FD1-A67A-980BE89E7FBEQ63597364-72B19EAE-EA03-45E7-BD0B-73C7C3A12B5DQ63813232-A5CBA712-6D61-4BE6-9C0D-C101C6179FF4
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Cediranib
@fr
Cediranib
@sh
Cediranib
@sr
cediranib
@en
type
label
Cediranib
@fr
Cediranib
@sh
Cediranib
@sr
cediranib
@en
altLabel
4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
@en
AZD 2171
@en
Cediranib
@en
ZD 2171
@en
prefLabel
Cediranib
@fr
Cediranib
@sh
Cediranib
@sr
cediranib
@en
P129
P486
P592
P6366
P661
P662
P683
P129
P2067
450.206719
P231
288383-20-0
P232
P233
CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
P234
1S/C25H27FN4O3/c1-16-12-17-19( ...... 6-7,12-15,29H,3-5,8-11H2,1-2H3
P235
XXJWYDDUDKYVKI-UHFFFAOYSA-N
P2566
100.196.628
P267
P274
C₂₅H₂₇FN₄O₃
P3117
DTXSID10183035
P486
P592
CHEMBL491473